BPA members win 12 invitations to virtual national competition
Earning second place in the state Business Professionals of America competition is the Mariner Middle administrative support team, comprising (l-r) Audrey Hershelman, Regan Best, Bridgett Cole and Rylie Cathcart. SUBMITTED PHOTOS
Ellen Driscoll April 1, 2021
Mariner BPA President Carly Favoroso earned the Diplomat Torch Service Award and first place in extemporaneous speech.
Alexa Valentin-Pegueros won first place in graphic design promotion.
Adria Windish, left, and Ellianna Windsor won third place in video production; teammate Maggie Minto is not pictured.
Ava Calciano netted third place in keyboarding production.
Maggie Minto won third place in graphic design promotion and was also part of the third-place video production team.
Credit: The Wistar Institute
PHILADELPHIA (Jan. 12, 2021) Scientists at The Wistar Institute have created an advanced humanized immune system mouse model that allows them to examine resistance to immune checkpoint blockade therapies in melanoma. It has revealed a central role for mast cells. These findings were published today in the journal
Nature Communications.
Checkpoint inhibitors revolutionized therapeutic options for advanced melanoma. However, only a fraction of patients respond to this treatment and some relapse due to reemergence of therapy-resistant lesions. To better understand why some cancers do not respond or become resistant to checkpoint therapies, we need more preclinical models that mimic the human tumor immune environment, said Rajasekharan Somasundaram, Ph.D., a member of The Wistar Institute Melanoma Research Center, who is the first and corresponding author of the paper.